Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia

NCT05232227 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05232227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Lead sponsor
University of California, San Francisco
Phase
Phase 2/3
Overall status
Withdrawn
Start date
January 20, 2023
Completion date
October 30, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, vivax, relapse